Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents (DAA) therapy is associated with >95% sustained virological response . Although the goal of HCV treatment is to achieve SVR, patients with advanced fibrosis and cirrhosis still have a high risk of developing HCC. It is important to identify patients who are at risk for liver disease complications after achieving SVR.

This study aims to :

• To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in evaluating changes in fibrosis and inflammation post-DAA therapy
•  To identify risks associated with HCC and liver disease progression after HCV cure post-DAA.